| Assessment Status | NCPE Assessment Process Complete |
| HTA ID | 22036 |
| Drug | Atezolizumab |
| Brand | Tecentriq® |
| Indication | As an adjuvant treatment following complete resection and platinum-based chemotherapy for adult patients with NSCLC with a high risk of recurrence whose tumours have PD-L1 expression on ≥ 50% of tumour cells and who do not have EGFR mutant or ALK-positive NSCLC. |
| Assessment Process | |
| Rapid review commissioned | 18/05/2022 |
| Rapid review completed | 02/06/2022 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of atezolizumab compared with the current standard-of-care. |
| Full pharmacoeconomic assessment commissioned by HSE | 01/07/2022 |
| Pre-submission consultation with Applicant | 04/10/2022 |
| Full submission received from Applicant | 02/12/2022 |
| Preliminary review sent to Applicant | 05/05/2023 |
| NCPE assessment re-commenced | 02/06/2023 |
| Factual accuracy sent to Applicant | 06/07/2023 |
| NCPE assessment re-commenced | 12/07/2023 |
| NCPE assessment completed | 20/07/2023 |
| NCPE assessment outcome | The NCPE recommends that atezolizumab (Tecentriq ®) should not be considered for reimbursement unless cost-effectiveness can be improved relative to existing treatments*. |
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations, March 2024.
